Physician profile
Krystle Bates
NPI 1326433657
$9,376.54
in general payments reported to CMS, 2019-2025
39 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $1,510 · 2021: $1,841 · 2022: $1,192 · 2023: $1,145 · 2024: $1,287 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,499.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,017.92 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $882.40 | 2019-2023 | Otezla, Repatha |
| Abbvie INC. | $868.95 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $818.86 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $737.01 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $732.48 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $498.25 | 2020-2024 | |
| Amarin Pharma, INC. | $391.38 | 2019-2022 | |
| Pfizer INC. | $378.19 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.84 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $363.72 | 2019-2024 | Belsomra, Steglatro, Proquad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.18 | 2019-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $281.51 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $175.14 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $144.32 | 2021-2023 | Freestyle Libre 3 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystle Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.